Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15
2024年8月5日 - 10:00PM
ビジネスワイヤ(英語)
ILiAD Biotechnologies, LLC (ILiAD), a biotech company developing
the most advanced next generation pertussis vaccine (BPZE1),
announced today that Fierce Biotech has named the Company to the
Fierce 15 2024 list (link), identifying ILiAD as one of the most
promising and innovative biotechnology companies in the
industry.
ILiAD’s BPZE1 intranasal pertussis vaccine has been studied in
four Phase 2 clinical trials in adults and school age children and
has demonstrated safety, induction of both mucosal and systemic
antibody responses, and protection against B. pertussis
colonization from both attenuated and virulent B. pertussis
challenge. Although pertussis is underappreciated and
underdiagnosed, the WHO has identified pertussis as the most
prevalent vaccine-preventable disease of children. In 2024, despite
high global vaccination rates with current pertussis vaccines,
major pertussis outbreaks have been observed around the world,
reinforcing the need for a new pertussis vaccine with greater
vaccine durability and the ability to prevent transmission to
vulnerable individuals.
Keith Rubin, M.D., ILiAD Chief Executive Officer and Founder
remarked, “We are grateful to be recognized as a Fierce 15 company.
From day one, we have been resolute in our mission to eradicate all
disease due to B. Pertussis. Fierce Biotech’s recognition of these
efforts and our progress affirms the great work of our dedicated
team and the potential of BPZE1 to positively impact global public
health.”
Since its founding in 2012, ILiAD has achieved numerous
scientific milestones, including development of the first pertussis
vaccine to demonstrate prevention of nasal colonization in a
virulent controlled human infection model (CHIM). The importance of
this achievement is highlighted by studies suggesting that B.
pertussis transmission, including transmission to vulnerable
infants, often occurs from individuals who are colonized with B.
pertussis but do not have classic whooping cough symptoms.
ILiAD has raised over $100M in financing to date.
Fierce Biotech is an internationally recognized daily report
reaching a network of over 450,000 biotech and pharma industry
professionals. Every year Fierce Biotech evaluates hundreds of
early-stage companies from around the world for its annual Fierce
15 list, which is based on a variety of factors such as the
strength of technology, partnerships, venture backers and
competitive market position. Past winners include biotechs that
have gone on to have greater than $5 billion in market
capitalization, including Moderna, MyoKardia, Acceleron Pharma, and
CRISPR Therapeutics. A substantial number of Fierce 15 recipients
have also subsequently been acquired by large pharmaceutical
companies, including Teva, Sanofi, GSK, Gilead, J&J, Bristol
Myers Squibb and Astra Zeneca.
About ILiAD Biotechnologies, LLC
ILiAD Biotechnologies (http://www.iliadbio.com) is a privately
held, clinical stage biotechnology company dedicated to the
prevention and treatment of human disease caused by Bordetella
pertussis. The company is developing and acquiring key
technologies, working with leading scientists to overcome the
limitations of current vaccines, investigating the impact of B.
pertussis in a range of human disease, and is focused on validating
its proprietary vaccines in human clinical trials.
About Pertussis
Pertussis (whooping cough) is a life-threatening disease caused
by the highly contagious respiratory bacterium Bordetella
pertussis. According to U.S. Centers for Disease Control and
Prevention, each year pertussis affects approximately 16 million
people globally, accounting for nearly 200,000 deaths. Although
estimated global vaccination coverage is 84%, current vaccines have
failed to control epidemics.
About BPZE1
BPZE1 is a next-generation live-attenuated pertussis vaccine
designed to induce comprehensive and durable protection against B.
pertussis infection (colonization) and disease (whooping cough).
BPZE1 is being developed to block B. pertussis from colonizing the
nasal passages of adults and children, to protect adults and
children from whooping cough, and to potentially prevent
transmission, including transmission to infants. While ILiAD is
currently focused on developing a vaccine to directly protect
adults and children and to indirectly protect vulnerable infants,
future development aims to immunize neonates directly. BPZE1 was
developed at the Institut Pasteur de Lille (France) in the lab of
Camille Locht PhD and Nathalie Mielcarek PhD.
“Safe Harbor” Statement under the Private Securities
Litigation Reform Act of 1995.
In addition to historical facts or statements of current, this
press release may contain forward-looking statements.
Forward-looking statements provide ILiAD’s current expectations or
forecasts of future events. These may include statements regarding
anticipated development of potential products, interpretation of
clinical results, prospects for regulatory approval, outsourcing
trends in the pharmaceutical industry, levels of industry research
and development spending, rapid technological change, risks
associated with acquisitions and investments, risks associated
directly with BPZE technologies including but not limited to
uncertainties of product development, and uncertainties of clinical
development, dependence on third parties, competition, protection
of patents and proprietary technology, potential for infringement
and other statements regarding matters that are not historical
fact. Some of these forward-looking statements may be identified by
use of words in the statements such as “estimate,” “intend,” or
other words and terms of similar meaning. Statements in this
release are not guarantees of future performance and involve
certain risks, uncertainties and assumptions, which are difficult
to predict. Therefore, actual outcomes and results may differ
materially from what is expressed in such forward-looking
statements. ILiAD cautions investors not to place reliance on the
forward-looking statements contained in this press release. These
statements speak only as of the date of this release and ILiAD
undertakes no obligations to update or review these statements,
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240802092354/en/
Ken Solovay COO ILiAD Biotechnologies, LLC Info@iliadbio.com
800.603.3525